MYOK MyoKardia Inc.

68.96
-0.98  -1%
Previous Close 69.94
Open 70.73
Price To Book 7.04
Market Cap 3,187,739,236
Shares 46,225,917
Volume 236,381
Short Ratio
Av. Daily Volume 414,784
Stock charts supplied by TradingView

NewsSee all news

  1. MyoKardia to Present at 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare

  2. MyoKardia to Present at Evercore ISI 2nd Annual HealthCONx Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 2nd

  3. MyoKardia Announces 48-week Data from PIONEER-OLE Study of Mavacamten

    Mavacamten's Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM Evidence Suggests Mavacamten's Favorable Impact on

  4. MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten

    Achieved Primary Study Objective of Safety and Tolerability in Patients with Non-obstructive HCM Significant Reductions in Biomarkers of Cardiac Stress Observed in Patients on Treatment vs. Placebo Data Support

  5. MyoKardia to Present at Credit Suisse 28th Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Credit Suisse

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 2Q 2020.
Mavacamten (MYK-461) - EXPLORER-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2 updated data released November 11, 2019.
Mavacamten (MYK-461) - PIONEER-OLE
Non-obstructive Hypertrophic cardiomyopathy (HCM)
Phase 2 top-line data met primary endpoint. 5 patients exhibited ejection fraction reductions below 45% - November 11, 2019.
Mavacamten (MYK-461) - MAVERICK-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2 genetic dilated cardiomyopathy (DCM) trial to commence 1H 2020.
MYK-491
Dilated cardiomyopathy (DCM)
Phase 1 top-line data due mid-2020.
MYK-224
Hypertrophic cardiomyopathy (HCM)

Latest News

  1. MyoKardia to Present at 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare

  2. MyoKardia to Present at Evercore ISI 2nd Annual HealthCONx Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 2nd

  3. MyoKardia Announces 48-week Data from PIONEER-OLE Study of Mavacamten

    Mavacamten's Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM Evidence Suggests Mavacamten's Favorable Impact on

  4. MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten

    Achieved Primary Study Objective of Safety and Tolerability in Patients with Non-obstructive HCM Significant Reductions in Biomarkers of Cardiac Stress Observed in Patients on Treatment vs. Placebo Data Support

  5. MyoKardia to Present at Credit Suisse 28th Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Credit Suisse

  6. MyoKardia Reports Third Quarter 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today reported financial results for the quarter ended September 30, 2019. "As we look across the milestones recently

  7. MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019

    SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced the presentation of several abstracts at the upcoming American Heart Association (AHA) Scientific Sessions

  8. MyoKardia to Present at 2019 Cantor Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that Taylor Harris, Chief Financial Officer, will participate in a fireside chat at the 2019 Cantor Global

  9. MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients

    SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy (SRT). The study

  10. MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019

    Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers Maintained,

  11. MyoKardia to Participate in September Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK), today announced its participation in the following upcoming investor conferences: Citi 14th Annual Biotech Conference in

  12. MyoKardia Announces Abstracts Selected for Presentation at the European Society of Cardiology Congress 2019

    SOUTH SAN FRANCISCO, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ:MYOK) today announced the presentation of three abstracts at the upcoming European Society of Cardiology (ESC) Congress taking